Johnson & Johnson ups offer for Guidant
This article was originally published in Clinica
Executive Summary
In yet another twist in the Guidant acquisition saga, Johnson & Johnson has agreed to fork out an additional $1.7bn for the cardiology company, raising its bid to $23.2bn. This marks the second revision to J&J's offer to buy Guidant, the previous one made in November 2005 when the healthcare giant cut its original offer of $25.4bn by nearly $4bn as a result of the troubles caused by Guidant's recalls.